New COVID Studie Q 1/22
It should also be noted that our other study is now being continued. It would not be published properly yet. The continuation of this study was responsible for the price drop from 40 to the current level. In the next few weeks, 3 large conferences will take place where the company We will report on it, so it will be made available to the general public. So we will have 2 strong Katylasoren in the next few weeks